Karyopharm eyes Xpovio filing in myelofibrosis on mixed data

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.

FDA clears Karyopharm’s myeloma drug despite advisory panel ...